Travere Therapeutics (TVTX) Receivables - Net (2014 - 2026)
Travere Therapeutics' (TVTX) quarterly Receivables - Net came in at $87.3 million in Q1 2026, up 153.78% YoY from $34.4 million in Q1 2025, and up 8.99% on a QoQ basis from $80.1 million in Q4 2025.
Travere Therapeutics (TVTX) Receivables - Net (2014 - 2026) Analysis & Trends
Travere Therapeutics (TVTX) has 13 years of Receivables - Net data on file, last reported at $87.3 million in Q1 2026.
- Quarterly Receivables - Net rose 153.78% year-over-year to $87.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $87.3 million (up 153.78% YoY) and the FY2025 annual result came in at $80.1 million, up 195.52% from the prior year.
- Receivables - Net improved to $87.3 million in Q1 2026, from $80.1 million in the prior quarter.
- In the past five years, Receivables - Net ranged from a high of $87.3 million in Q1 2026 to a low of $12.7 million in Q3 2022.
- A 5-year average of $33.0 million and a median of $22.7 million in 2024 frame the typical range for Receivables - Net.
- Annual changes were most pronounced in 2022 — Receivables - Net declined 5.22% — and 2025, when it soared 229.37%.
- Tracing TVTX's Receivables - Net over 5 years: stood at $16.6 million in 2022, then climbed by 27.23% to $21.2 million in 2023, then advanced by 28.03% to $27.1 million in 2024, then soared by 195.4% to $80.1 million in 2025, then rose by 8.99% to $87.3 million in 2026.
- The last three Receivables - Net figures came in at $87.3 million (Q1 2026), $80.1 million (Q4 2025), and $83.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Travere Therapeutics | 5.85 Bn | 5.85 Bn | 162.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 80.64 Mn |
| Jun 30, 2026 | 80.64 Mn |
| Mar 31, 2026 | 87.30 Mn |
| Mar 31, 2026 | 87.30 Mn |
| Dec 31, 2025 | 80.10 Mn |
| Dec 31, 2025 | 80.10 Mn |
| Sep 30, 2025 | 83.00 Mn |
| Sep 30, 2025 | 83.00 Mn |
| Jun 30, 2025 | 38.72 Mn |
| Jun 30, 2025 | 38.72 Mn |
| Mar 31, 2025 | 34.40 Mn |
| Mar 31, 2025 | 34.40 Mn |
| Dec 31, 2024 | 27.12 Mn |
| Dec 31, 2024 | 27.12 Mn |
| Sep 30, 2024 | 25.20 Mn |
| Sep 30, 2024 | 25.20 Mn |
| Jun 30, 2024 | 24.47 Mn |
| Jun 30, 2024 | 24.47 Mn |
| Mar 31, 2024 | 22.73 Mn |
| Mar 31, 2024 | 22.73 Mn |